

Review Article

DOI: 10.22114/ajem.v0i0.117

Management of Violence and Aggression in Emergency Environment; a Narrative Review of 200 Related ArticlesMaryam Ziaei¹, Ali Massoudifar², Ali Rajabpour-Sanati³, Ali-Mohammad Pourbagher-Shahri³, Ali Abdolrazaghnejad^{1*}

1. Department of Emergency Medicine, Khatam-Al-Anbia Hospital, Zahedan University of Medical Sciences, Zahedan, Iran.

2. Department of Psychiatry, School of Medicine, Hormozgan University of Medical Sciences, Bandarabbas, Iran.

3. Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.

Corresponding author:** Ali Abdolrazaghnejad; Email: ali.abdorazzagh@gmail.com**Abstract*Context:** The aim of this study is to reviewing various approaches for dealing with agitated patients in emergency department (ED) including of chemical and physical restraint methods.**Evidence acquisition:** This review was conducted by searching "Violence," "Aggression," and "workplace violence" keywords in these databases: PubMed, Scopus, EmBase, ScienceDirect, Cochrane Database, and Google Scholar. In addition to using keywords for finding the papers, the related article capability was used to find more papers. From the found papers, published papers from 2005 to 2018 were chosen to enter the paper pool for further review.**Results:** Ultimately, 200 papers were used in this paper to conduct a comprehensive review regarding violence management in ED. The results were categorized as prevention, verbal methods, pharmacological interventions and physical restraint.**Conclusion:** In this study various methods of chemical and physical restraint methods were reviewed so an emergency medicine physician be aware of various available choices in different clinical situations for agitated patients.**Key words:** Aggression, Emergency Service, Hospital, Restraint, Physical, Violence**Cite this article as:** Ziaei M, Massoudifar A, Rajabpour-Sanati A, Pourbagher-Shahri AM, Abdolrazaghnejad A. Management of Violence and Aggression in Emergency Environment; a Narrative Review of 200 Related Articles. Adv J Emerg Med. 2019;3(1): e7.**CONTEXT**

Workplace Violence (WPV) of medical personnel has diverse forms, accounting for one of the potential risk factors in society (1-7). Among different jobs, medical personnel are the most vulnerable groups to WPV; some studies have shown that the probability of WPV for medical personnel is higher than that for police officers and prison guards (8). Today, accurate statistics of WPV are not available for some reasons such as unavailability of a unique definition and effective deterrent rules (9-11). However, based on available data, 35 to 80% of medical personnel, especially emergency department (ED) personnel, experienced physical violence at least once, and 100% of them experienced verbal violence in their career (12-14). WPV is highly prevalent as almost 25% of respondents in one study in the United States that was published in 2009, reported experiencing physical violence more than 20 times in the past 3 years (15). WPV is associated with severe financial and psychological costs such as career burnout, depression, fear, post traumatic stress disorder (PTSD), decreased job satisfaction,

reduced performance, or even career quitting (9, 16-18). This phenomenon, in addition to the medical personnel, can harmfully affect the offender and the other patients, as there are some reported cases of death following excited delirium (19). Among the different departments of hospitals, the emergency department is one of the most vulnerable departments toward violence of the patients; one of its reasons is lack of well-trained and armed security guards that are apparent to patients (12, 20-22). Stressful and special conditions of the emergency department and critical state of its patients are other reasons for the stimulus of physical and verbal violence toward its personnel (20). The constant rising violence phenomenon in emergency departments has been highly discussed in numerous studies (23-25), and some government agencies have tried to establish deterrent rules against WPV via intensifying the punishment of offenders (26-28). However, based on evidence and experience of medical personnel, these rules alone, are not competent enough and in many cases, direct act from medical personnel is needed. The importance and high prevalence of

this phenomenon and the need of knowing effective approaches for medical personnel to control and act directly in WPV situations were the purposes of this review article.

EVIDENCE ACQUISITION

This review was conducted by searching "Violence," "Aggression," and "workplace violence" keywords in these databases: PubMed, Scopus, EmBase, ScienceDirect, Cochrane Database, and Google Scholar. In addition to using keywords for finding the papers, the related article capability was used to find more papers. From the found papers, published papers from 2005 to 2018 were chosen to enter the paper pool for further review. As this article was conducted as a review, no independent data from direct clinical interventions or field collection were entered the study; therefore, no written consent was needed. Ultimately, 200 papers were used in this paper to conduct a comprehensive review of the management of violence in ED.

RESULTS

Ultimately, 200 papers were used in this paper to conduct a comprehensive review regarding violence management in ED. The results were categorized as prevention, verbal methods, pharmacological interventions and physical restraint.

Prevention

One of the highly recommended methods in many articles is to train medical personnel to determine and take necessary measures with the patients in the edge of losing control; as these courses are mandatory in some healthcare centers (29). However, some studies have questioned the effectiveness of these courses (30). Among the medical personnel, triage nurses are the first line exposed to violence and aggression of clients (25, 31, 32). Therefore, the ability to determine the alarming signs of the beginning of violence is highly essential in preventing and taking proper actions. Among the different methods of screening and identification of warning signs of violence, STAMP (33), STAMPEDAR (34) are the fastest and most practical methods useable in triage. In addition, other used methods include Brief Agitation Rating Scale (35), Clinical Global Impression Scale for Aggression (36), Historical-Clinical-Risk Management-20 Violence Risk Assessment Scheme (37), and Positive and Negative Syndrome Scale-Excited Component (38-41).

Violence management in emergency

Actions used to manage the patient with violence episode in an emergency environment consist of verbal, physical, mechanical methods and various pharmacological methods that can be combined based on situations (42, 43). As there are possibilities of physical and psychological harm, retraumatization, loss of dignity, and even death, especially in physical and mechanical restraint (44, 45), it is necessary to identify the advantages and disadvantages of every method to choose the best option. As evidenced by some studies, contrary to old methods and beliefs, it is recommended that use of mechanical and physical restraint should be reduced to significantly decrease the complications and prevent the patient isolation, which can predispose future violent actions (44, 45). Most medical personnel consider control of violence and agitation of the patient an easy task, particularly in recent years, haloperidol use has increased in emergency departments (46-49). However, some studies have shown that this drug and controlling method has not shown desirable results all the time. In the following, different methods of managing violence in patients in the emergency environment will be reviewed.

Verbal methods

The first task when confronting a patient with violent and agitated behavior is the evaluation and improvement of the environmental setting to increase the security of people on stage (50). In line with the mentioned task, some rules should be generally considered:

- Assuring patient's physical safety
- Reducing environmental triggers and isolating the patient
- Reducing the patients waiting time
- Removing potentially dangerous objects
- Observing and evaluating the used approach by healthcare staff toward the patient
- Making efforts toward establishing a safe, private, and caregiving communication with the patient, and staying calm
- Maintaining safe distance with the patient
- Identifying possible causes of patients violence
- Respecting and maintaining the privacy of the patient
- Avoiding direct and harsh encounter with the patient
- Avoiding prolonged and intense direct eye contact with the patient
- Avoiding using any threatening body language

The very first therapeutic method in approach toward the agitated and aggressive patient is

verbal de-escalation (Defusing or talking down). This method helps the patient to understand the empathy and professional concern of the medical personnel and assure the patient that purpose of the medical team is his/her well-being and safety, and no danger threats him/her (50). In some situations, and if available, help and consults from social services consultants can also be used (51).

Pharmacological interventions

• First-generation antipsychotics (Typical)

First-generation antipsychotics (FGAs) are more commonly used drugs to control and treat aggression and agitation in patients (52), and their effects are due to inhibition of dopaminergic transmission in the brain (46). Despite the widespread use of these drugs, their effectiveness and side effects are among the discussed issues in the studies (52). Usage of these drugs has potential risks for development of extrapyramidal and tardive dyskinesia side effects (53).

Based on high- or low-potency, these drugs are divided as follows:

- The first division, the high-potency FGAs consist of fluphenazine, haloperidol, loxapine, perphenazine, pimozide, thiothixene, and trifluoperazine
- The second division, the low-potency FGAs consist of chlorpromazine and thioridazine

Among the first division drugs, fluphenazine, haloperidol, loxapine, pimozide, and thiothixene have the highest risk for development of Extrapyramidal Syndrome (EPS) (53). Based on one study by Gao et al., 21 to 31% of patients under treatment with haloperidol for 3 to 8 weeks developed drug-induced EPS (54). The second division drugs of FGAs have a lower risk of EPS development and are comparable with the second-generation antipsychotics drugs such as risperidone (55).

A) Haloperidol

Haloperidol is a highly potent neuroleptic that can induce a proper sedative effect if administrated intramuscular (56). Despite the side effects of this drug that can occur even after one-time injection, it is still used worldwide in emergency set-up (47, 51) and the main reasons for that are lower complications such as excessive sedation and hypotension compared to the same generation drugs (48, 57, 58). However, haloperidol alone, can induce dangerous EPS complications such as acute dystonia (59). In addition to EPS, studies have shown that high doses of intravenous haloperidol can cause prolonged QT and TdP in electrocardiogram (60-65). These complications

have become more prominent considering the fact that haloperidol is the most used drug for controlling acute agitation in the world, and it is the treatment of choice in some healthcare centers (46, 51).

B) Chlorpromazine

Discovery of chlorpromazine in 1952 was named the "psychopharmacological revolution" in the treatment of psychological diseases (66, 67). Nevertheless, future studies showed that use of this drug for rapid tranquilization was not a suitable choice in clinical settings due to local hypersensitivity and discomfort following intramuscular injection. Furthermore, there is a well-documented potential risk for cardiovascular disease when using needed doses of this drug for rapid tranquilization of the patient (68). However, in a Cochrane review conducted by Ahmed et al., no statistically significant difference was found between EPS complications owing to using haloperidol and chlorpromazine (69).

• Second-generation antipsychotics (Atypical)

The newest turning point in the treatment of psychosis and acute agitation in patients has been the production of second-generation antipsychotics (Atypical) that have less EPS complications (70, 71), hyper prolactinoma (72), and movement disorders (58, 71) compared to their previous generations. The most important drugs of this generation are Risperidone, Olanzapine, Ziprasidone, Aripiprazole, and Quetiapine (73, 74). In some drugs of this generation (e.g. risperidone and olanzapine), there is a direct relation between the administered dose and incidence of EPS, whereas in some other drugs (e.g. clozapine and quetiapine), this relation is not apparent (71). It is important to point out that some trials have questioned the advantages of these antipsychotics in speed on onset (75) and degree of response (76, 77) compared to the previous generation and even haloperidol alone (78, 79), and even some studies have considered this two generation to have a one category (46, 80). Furthermore, notwithstanding the benefits of this generation of drugs and their superiority in reducing morbidity and mortality, their prolonged use can induce complications such as overweighting, disruption of glucose metabolism, dyslipidemia, and cardiovascular disease (81). Based on available guidelines, to control the patient's symptoms, monotherapy is preferred over polytherapy, and according to a general rule, an administrated dose of the drug should be equal to 300 to 1000 chlorpromazine to reduce the incidence of a dangerous side effect (82, 83). One of

the main problems of using atypical antipsychotic drugs in an emergency is a limited number of the performed randomized clinical trial concerning these drugs in emergency setup (80, 84-91). Many of the studies into using these drugs have been conducted on recently admitted agitated patients (79, 92, 93). This can be one of the main obstacles facing emergency medicine physicians when choosing and using these drugs. Nevertheless, most of the conducted studies in different hospital settings confirm high effectiveness of these drugs compared to haloperidol (Either same effectiveness or higher) in the treatment of the agitated patient (79, 87, 91, 94, 95).

A) Risperidone

It is a second-generation antipsychotic drug administered in variable ways (96); even in its oral intake form (Risperidone OS), it is efficient as much as other forms (97). Furthermore, there is no statistically significant difference between the oral form of risperidone and injected haloperidol regarding compliance, the speed of onset, and effectiveness (98). Villari et al. in their study observed that risperidone, olanzapine, and quetiapine were effective as much as haloperidol, and interestingly they showed its better compliance compared to haloperidol (99). In addition to its advantageous position to atypical antipsychotics, it has shown equal or better action compared to some typical antipsychotics such as zuclopenthixol (100).

B) Olanzapine

Olanzapine is one of the second-generation antipsychotics and is a dopamine/serotonin antagonist that Its effect on controlling and relaxing patients in the injectable and oral administration is higher than intramuscular haloperidol in the first 90 minutes and after that, the effects are equal (96). According to the study of Pascual et al., oral administration of 20 milligrams of olanzapine was effective in rapid and safe improvement of acutely agitated patients (101). Although oral administration of olanzapine (Olanzapine ODT) is more effective than its injectable form, studies have not shown any statistically significant difference (96). Since intramuscular administration of olanzapine is effective and safe in improving and treating agitated patients (102, 103), choosing between different forms of administration is related to circumstances and physician's opinion. In one study by Castle et al., intramuscular administration of olanzapine compared to other antipsychotics was more effective in improving patients' symptoms two hours after administrations, and the

results were statistically significant (104); there are more studies confirmative of this result (84, 90). In this regard, studies have indicated better or equal effects of olanzapine compared to haloperidol (99, 105, 106). Other advantages of olanzapine use in managing agitated patients are that the need for other antipsychotic, anticholinergic, and anxiolytic/hypnotic drugs administration is reduced compared to other drugs (104, 107). In one study by Kinon et al., no statistically significant difference was found between the effects of using olanzapine and aripiprazole (both with co-administration of lorazepam). The most observed side effect in olanzapine use was insomnia (5.2%) and in aripiprazole was insomnia (8.3%) and headache (5.3%) (108). It is important to know that concurrent administration of intramuscular olanzapine with benzodiazepines increases the probability of occurring side effects (109-111); olanzapine can affect the Alpha-1 receptors and induce hypotension (112).

C) Quetiapine

In contrast to other atypical antipsychotics and like olanzapine, it has a high affinity toward antihistaminic receptors; therefore, it poses a higher sedative effect on the patient compared to other drugs of its generation (48). Drowsiness and orthostasis are among the most reported side effects of this drug. These side effects can be a limiting factor for their use in patients with dehydration and electrolytes imbalance (113, 114).

D) Ziprasidone

Ziprasidone was the first drug of atypical antipsychotic drugs in injectable form (86). Compared to other atypical antipsychotic drugs, its affinity toward serotonin receptors compared to D2 receptors is 10-folds (115). Based on conducted clinical trials, this drug can improve the symptoms of an agitated patient in 15-30 minutes (116). Though this drug like other drugs in its generation has lower side effects (e.g. EPS, dystonia, and oversedation), but the danger of QTc prolongation and cardiac arrhythmia still exist (117). Despite this, Jangro et al. study showed that monotherapy with intramuscular ziprasidone could induce an effective and relevant sedative effect compared to the combined use of haloperidol and lorazepam (86).

E) Aripiprazole

Among the variable atypical antipsychotic drugs, there is Aripiprazole that different studies have showed its high effectiveness (up to 90% of patients) in intramuscular administration (92, 93, 118). No statistically significant relationship has

been found between clinical effectiveness and its blood serum levels; this is similar to most of the atypical antipsychotics drugs (except olanzapine (118-120). This is one of the challenges ahead of clinical practice in using Aripiprazole that can affect acquiring therapeutic levels and controlling its side effects. However, some of its side effects such as sedation can be compared to drugs such as lorazepam; as in one study by Zimbrow et al., levels of effectiveness of Aripiprazole were the same as intramuscular lorazepam, but it showed lower sedative effects (92).

• Benzodiazepines

Benzodiazepines, with their anxiolytic and sedative effects, can cause rapid agitation of the patient. However, their side effects such as respiratory depression, excessive sedation, ataxia, and paradoxical disinhibition limit their usage (46, 121-128).

A) Lorazepam

Other drugs that can be used to control patients with agitation are lorazepam, which has positive outcomes particularly in combination with haloperidol (91); therefore, the most commonly used antipsychotic combination in the United States is haloperidol+lorazepam (129). However, a 2005 Cochrane review study found that there was insufficient evidence to suggest a superior benefit in a combination of haloperidol+lorazepam than other antipsychotics such as haloperidol+promethazine (130). In addition, its IM form is not readily available in many regions (56).

B) Diazepam and Midazolam

Diazepam along with haloperidol, lorazepam, midazolam, and chlorpromazine have been controversial in tolerability profiles in studies (131). Among these drugs, diazepam and midazolam have a potential risk for respiratory depression, especially in high-risk patients and those with metabolic disorders of benzodiazepines (such as hepatic impairment and alcohol users) (131-133). Diazepam, as with lorazepam, is also contraindicated in patients suspected of being poisoned with Propylene glycol (131). Despite these complications, some studies have indicated better effects of midazolam on psychomotor agitation than haloperidol (73).

• Other drugs

A) Promethazine

Studies have shown that this anti-histamine, especially in combination with haloperidol (59), can be useful in acute improvement of the patient's agitation in emergencies. The reason for this drug combination is to accelerate the final results following sedative and antimuscarinic effects of

promethazine (56, 80, 117, 129). However, the combination of this drug with olanzapine is not recommended due to increased likelihood of symptomatic hypotension, particularly in alcohol users (112, 134).

Physical restraint

Physical restraint refers to a set of actions taken on the body or near the patient's body to limit the degree of freedom of movement (135, 136). Restraining the patients is performed in two ways: Physical restraining whereas some areas of the patient's body is held by other people and mechanical restraining whereas the movements of the patient are limited by using approved devices and appliances such as straps (leather and cloth) and belts (18, 137-140). Most of the times, the term "physical restraint" is used to refer to the two above-mentioned ways. Physical restraint is performed in various ways: limiting the movements of limbs and body on specific beds with straps [4 points (ankles and wrists) and 5 points (ankles, wrist, and chest)]; fasten the patient on chair and limiting the movements of limbs (Ambulatory restraint); limiting the whole-body movement by camisole or straightjacket. When restraining patients, there should be some considerations: either restraint the 4 limbs or none, since freedom of one limb can cause many problems and complications; to prevent kicking from the patient, right leg can be tied up to the left corner of the bed, and the left leg can be tied up to the right corner of the bed; using a soft padding beneath the skin of restrained ankles and wrists; unlocking the fastened parts of the patient's body in periodical manner to prevent the possible complications; moving the body of the patient every 2 hours; examination distal of the limbs for sensory and neurological signs; immobilizing the chest or waist to prevent falling down from the bed; checking patients respiratory rate every hour; for patients that are in the wheelchair, chest should be immobilized not the waist (141-143).

There are some rules provided by "American College of Emergency Physicians (ACEP)" for physical restraint usage (144):

- It should be used only after verbal de-escalation
- Privacy and dignity of the patient should be maintained during the physical restraint
- Limitation should be as low as possible
- Medical personnel should be properly trained for using physical restraint and monitoring the patient under physical restraint
- The existence of appropriate protocols to ensure patient safety, including the necessary

care and treatment during the period of physical restraint and periodic evaluations to determine whether to maintain physical restraint

- The patient under physical restraint should be explicitly and continuously observed by his or her physician
- The use of physical restraint should be consistent with standards and rules.

Owing to the possibility of complications and the use of physical restraint, which may be subject to pressure and threats and punishment, it is difficult to make decisions about physical restraint (142).

DISCUSSION

Based on conducted studies, a significant portion of violence in an emergency environment is caused by patients (88.2%) aged between 20 and 30 years, and with male sex (64.7%). Alcohol use (52.3%), methamphetamine and other drugs abuse (5%), long waiting hours (11.9%) (11, 145-147), suicidal thoughts (13.8%) (145), high severity of previous violence of patient (148), inadequate number of personnel (149), weak safety proceedings (150), an out-of-sight security team (151, 152), crowded and busy emergency unit (153), time of the patient arrival (evening and night shifts) (23), and weak ability of medical personnel in communicating with the patient and patient companion (154) are among the influencing factors (155).

Pharmacological interventions in the management of violent patients in emergency departments consist of using first-generation antipsychotics (especially haloperidol), benzodiazepines, and second generations antipsychotics (atypical). The most important fact that should be considered when choosing drugs is that the primary purpose of managing the violent patient in the emergency department is calming down and reducing agitation not over sedating the patient (73, 91, 156-159).

Physical restraint should provide acceptable protection against injury for the patient and others. Aggressive behavior can occur suddenly, and it should be considered that in the every moment, it occurs, the first reaction for controlling it, should always be verbal de-escalation (135, 160). Physical restraint is used when verbal de-escalation and pharmacological intervention are not effective, and the patient has dangerous and harmful behaviors for himself/herself and others (135, 161, 162). The goals of physical restraint are preventing harm and injury to physical and psychological integrity, and safety of the patient and other patients and medical personnel; preventing severe damage to the

healthcare center environment (135, 142, 163). Furthermore, physical restraint can provide a way for performing necessary therapeutic actions and grant the time for administrated drugs to reach their therapeutic levels (135, 162, 164, 165). From the beginning of the physical restraint, the reason for it should be declared for the patient so that it should be explained to the patient that the purpose of this action is not punishment and it is for the safety of the patient and others (161, 166). Physical restraint is always accompanied by numerous dangers and complications. Therefore, specific and detailed rules and instruction for its use should be available in every healthcare center.

Various factors affect the decision-making of medical personnel to apply physical restraint, including lack of alternative ways, underlying needs, escalation effects of restraint itself, and so on (167). Several hazards to the patient under physical restraint may occur, including the following: dehydration, choking, blood circulatory problems in under pressure areas and limbs, bedsore, losing power and movement by the patient, incontinence, thromboembolic incidents, Deep Vein Thrombosis, bone fracture, lactic acidosis, aspiration, stress cardiomyopathy, respiratory depression and asphyxia, and even death (57, 168-176). Preventing these complications is achieved via periodic and constant evaluations (166).

In one study by Cowman et al. conducted in 17 European countries, among mental health personnel (mental inpatient services, forensic, emergency, and so on), the results showed that the most common method of intervention against violence was to use physical restraint (177). One study showed that there was limited empirical evidence for using physical restraint to control the violence of admitted mentally ill patients (178). The use of physical restraint in mental patients, if not controlled, can tend to increase (179). One study in China showed a positive correlation between the use of physical restraint, unemployment, low incomes, and the amount of patients' aggression in the last month (180). In some countries such as Britain and the Netherlands, mechanical and physical restraint is against the law (57, 181). In Brazil, the most common way of controlling violence and invasion is to use physical restraint (57).

In recent years, many efforts have been made to reduce the use of physical restraint. In one study, a six-core strategy based on "Trauma Informed care" was used between young patients admitted to the hospital, the results showed that this strategy

reduced the use of physical restraint in young patients admitted to hospital. The main causes of using physical restraint were maladaptive behavior and mood disorders (182). Another study conducted on hospitalized patients in New York City could significantly reduce the amount of physical restraint during a 5-year period follow-up by employing several interventions, including reducing the timing of new orders for physical restraint, teaching staff to diagnose patients at risk for immediate intervention, and a questionnaire filled by patients that determined their own choices in When anxiety was detected (183). In one study by Martin et al., a "Collaborative problem solving" treatment program for children and adult patients reduced the use of physical restraint in children (184).

Owing to cultural and regional differences, it is difficult to create a universal protocol for using physical restraint. Physical restraint can influence the rate of acceptance of post-discharge treatment interventions by the patient after being discharged from the emergency department. In one study, the effect of physical restraint on the rate of referral for outpatient psychiatric visits after discharge was examined. The results showed that patients with physical restraint were less likely to conduct these post-discharge visits (185). In one study, the abundance and type of physical restraint used by ICU, emergency department, and neurosurgery nurses, their views on physical restraint, as well as the complications of this work in several hospitals in Turkey were investigated. Nurses performed physical restraint on ankle, hand or body at different levels. Those working in the surgical and emergency ICU sections having in-service training used more physical restraint. There were also 9 deaths. The reduction in the rate of services to patients was directly related to the complications of physical restraint (186). In one retrospective study conducted in a hospital over a 1-year period in patients with acute behavioral disorders referred to the emergency department that needed intervention, the results showed that from 122 cases with this condition, physical restraint alone was performed in 14 cases, and it was performed along with pharmacological therapy in 66 cases (187). In another study conducted by Dumais et al., results from a mental hospital in Canada showed that over 2 years, out of 2721 admitted patients, physical restraint was used in 476 cases (188). In another study, the use of physical restraint in patients over the age of 60 was determined by nurses to be patient safety and nurses' workload (189, 190). In another study in the emergency

department of four hospitals in Australia, results showed that physical restraint was used in 0.04% of the total number of referrals. The physical restraint was mainly carried out using a soft bracelet and soft sole. The average physical restraint time was 2 hours and 5 minutes (191).

There is a considerable difference between duration of physical inhibition in different areas. In one study, the average physical restraint time in 10 European countries varied from 4.5 hours to 1182 hours (137, 192). In one study, the relationship between the degree and type of physical restraint with age and sex and the history of immigration in a hospital in Norway was investigated. The results indicated that from 960 hospitalized patients, in 14% of them, physical restraint was used. Physical restraint was higher among immigrants and especially young people. Physical restraint alone was higher in local people, and along with drug interventions, it was higher in immigrants. Physical restraint was reduced at the age of 60 or more (193).

In one study investigating the first physical restraint experience in psychiatric wards over 2 years, the results indicated that physical restraint along with pharmacological intervention took longer than physical restraint alone (194). Another study found that patients who were periodically subjected to physical restraint were hospitalized more often and longer (195). In one study, the patients' opinion about physical restraint and possible improvement and alternative were investigated. The results demonstrated that failure to address and provide the patients' basic needs and lack of communication during the time of physical restraint were the most important factors among the mentioned problems (196). In another study, the study of patients' perceptions and impressions subjected to physical restraint revealed that patients were inadequately connected with medical staff and feel distorted and trampled on their human rights (197). Another study conducted by McCurdy et al. demonstrated that installation of a door between the patients' accessible area and the waiting area of the ward, significantly reduced the amount of physical restraint (198). A study performed in 3 psychiatric emergencies in Rio, Brazil on aggressive patients showed that of 301 patients, 73 of them were physically restrained in the first 2 hours after admission (199). Physical restraint can undermine the trust and relationship between the patient and the medical team members. A series of factors can reduce this damage. In this regard, one study by Khatib et al. showed that duration of the restraint,

contact with medical personnel during the period of physical restraint, supportive interventions of medical personnel and their response to the patient's needs were critical and significant factors in determining how the patient experienced physical restraint and its consequence (200).

CONCLUSIONS

In this study various methods of chemical and physical restraint methods were reviewed so an emergency medicine physician be aware of various available choices in different clinical situations for agitated patients.

ACKNOWLEDGEMENTS

REFERENCES

1. American Association of Occupational Health Nurses Unveils 2005 Public Policy Platform [Available from: https://www.ehstoday.com/news/ehs_imp_37420.
2. Zampieron A, Galeazzo M, Turra S, Buja A. Perceived aggression towards nurses: study in two Italian health institutions. *J Clin Nurs*. 2010;19(15-16):2329-41.
3. Alameddine M, Kazzi A, El-Jardali F, Dimassi H, Maalouf S. Occupational violence at Lebanese emergency departments: prevalence, characteristics and associated factors. *J Occup Health*. 2011;53(6):455-64.
4. Esmaeilpour M, Salsali M, Ahmadi F. Workplace violence against Iranian nurses working in emergency departments. *Int Nurs Rev*. 2011;58(1):130-7.
5. Rafati Rahimzadeh M, Zabihi A, Hosseini S. Verbal and physical violence on nurses in hospitals of Babol University of Medical Sciences. *Hayat*. 2011;17(2):5-11.
6. Hilliar K. Police-recorded assaults on hospital premises in New South Wales: 1996-2006. *Crim Just Bull*. 2008;16:1-12
7. Lau JB, Magarey J, McCutcheon H. Violence in the emergency department: a literature review. *Australas Emerg Nurs J*. 2004;7(2):27-37.
8. Nurses and Violence in the Workplace [Available from: <https://www.ausmed.com/articles/nurses-and-violence-in-the-workplace/>.
9. Ferns T. Violence in the accident and emergency department--an international perspective. *Accid Emerg Nurs*. 2005;13(3):180-5.
10. Kindy D, Petersen S, Parkhurst D. Perilous work: nurses' experiences in psychiatric units with high risks of assault. *Arch Psychiatr Nurs*. 2005;19(4):169-75.
11. Ryan D, Maguire J. Aggression and violence - a problem in Irish Accident and Emergency departments? *J Nurs Manag*. 2006;14(2):106-15.
12. Clements PT, DeRanieri JT, Clark K, Manno MS, Kuhn DW. Workplace violence and corporate policy for health care settings. *Nurs Econ*. 2005;23(3):119-24, 07.
13. Catlette M. A descriptive study of the perceptions of workplace violence and safety strategies of nurses working in level I trauma centers. *J Emerg Nurs*. 2005;31(6):519-25.
14. Pich J, Hazelton M, Sundin D, Kable A. Patient-related violence against emergency department nurses. *Nurs Health Sci*. 2010;12(2):268-74.
15. Gacki-Smith J, Juarez AM, Boyett L, Homeyer C, Robinson L, MacLean SL. Violence against nurses working in US emergency departments. *J Nurs Adm*. 2009;39(7-8):340-9.
16. Workplace violence position statement [Available from: <https://www.apna.org/i4a/pages/index.cfm?pageid=3786>.

We would like to thank all the faculties whom participated in this study.

AUTHORS' CONTRIBUTION

All authors passed four criteria for authorship contribution based on recommendations of the International Committee of Medical Journal Editors.

Conflict OF INTEREST

None declared.

FUNDING

None declared.

17. Association EN, editor Violence in the emergency department: Findings from ENA's study of workplace violence against registered nurses. Annual Conference Course; 2008.
18. van der Zwan R, Davies L, Andrews D, Brooks A. Aggression and violence in the ED: issues associated with the implementation of restraint and seclusion. *Health Promot J Austr.* 2011;22(2):124-7.
19. Vilke GM, DeBard ML, Chan TC, Ho JD, Dawes DM, Hall C, et al. Excited Delirium Syndrome (ExDS): defining based on a review of the literature. *J Emerg Med.* 2012;43(5):897-905.
20. Gerberich SG, Church TR, McGovern PM, Hansen H, Nachreiner NM, Geisser MS, et al. Risk factors for work-related assaults on nurses. *Epidemiology.* 2005;16(5):704-9.
21. Kennedy MP. Violence in emergency departments: under-reported, unconstrained, and unconscionable. *Med J Aust.* 2005;183(7):362-5.
22. Ashton RA, Morris L, Smith I. A qualitative meta-synthesis of emergency department staff experiences of violence and aggression. *Int Emerg Nurs.* 2018;39:13-9.
23. Ferns T, Cork A, Rew M. Personal safety in the accident and emergency department. *Br J Nurs.* 2005;14(13):725-30.
24. Hahn S, Hantikainen V, Needham I, Kok G, Dassen T, Halfens RJ. Patient and visitor violence in the general hospital, occurrence, staff interventions and consequences: a cross-sectional survey. *J Adv Nurs.* 2012;68(12):2685-99.
25. Lau JB, Magarey J, Wiechula R. Violence in the emergency department: an ethnographic study (part II). *Int Emerg Nurs.* 2012;20(3):126-32.
26. Workplace Violence [Available from: <https://www.nursingworld.org/practice-policy/advocacy/state/workplace-violence2/>].
27. Li YF, Chao M, Shih CT. Nurses' intention to resign and avoidance of emergency department violence: A moderated mediation model. *Int Emerg Nurs.* 2018;39:55-61.
28. Nordstrom K, Allen MH. Managing the acutely agitated and psychotic patient. *CNS Spectr.* 2007;12(10 Suppl 17):5-11.
29. Violence Prevention and Management Training Framework for NSW Health Organisations [Available from: https://www1.health.nsw.gov.au/pds/Pages/doc.aspx?dn=PD2017_043].
30. Wassell JT. Workplace violence intervention effectiveness: A systematic literature review. *Safe Sci.* 2009;47(8):1049-55.
31. Varcoe C. Staring, tone of voice, anxiety, mumbling, and pacing in the ED were cues for violence toward nurses. *Evid Based Nurs.* 2008;11(1):29.
32. Morphet J, Griffiths D, Plummer V, Innes K, Fairhall R, Beattie J. At the crossroads of violence and aggression in the emergency department: perspectives of Australian emergency nurses. *Aust Health Rev.* 2014;38(2):194-201.
33. Luck L, Jackson D, Usher K. STAMP: components of observable behaviour that indicate potential for patient violence in emergency departments. *J Adv Nurs.* 2007;59(1):11-9.
34. Chapman R, Perry L, Styles I, Combs S. Predicting patient aggression against nurses in all hospital areas. *Br J Nurs.* 2009;18(8):476, 8-83.
35. Lasalvia A, Bonetto C, Cristofalo D, Tansella M, Ruggeri M. Predicting clinical and social outcome of patients attending 'real world' mental health services: a 6-year multi-wave follow-up study. *Acta Psychiatr Scand Suppl.* 2007(437):16-30.
36. Huber CG, Lambert M, Naber D, Schacht A, Hundemer HP, Wagner TT, et al. Validation of a Clinical Global Impression Scale for Aggression (CGI-A) in a sample of 558 psychiatric patients. *Schizophr Res.* 2008;100(1-3):342-8.
37. Douglas KS, Guy LS, Reeves KA, Weir J. HCR-20 violence risk assessment scheme: Overview and annotated bibliography. 2005. Implementation Science and Practice Advances Research Center Publications. 335.

38. Sachs GS, Gaulin BD, Gutierrez-Esteinou R, McQuade RD, Pikalov A, 3rd, Pultz JA, et al. Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. *J Clin Psychiatry*. 2007;68(9):1377-83.
39. Currier GW, Citrome LL, Zimbroff DL, Oren D, Manos G, McQuade R, et al. Intramuscular aripiprazole in the control of agitation. *J Psychiatr Pract*. 2007;13(3):159-69.
40. Marder SR, West B, Lau GS, Pultz JA, Pikalov A, Marcus RN, et al. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. *J Clin Psychiatry*. 2007;68(5):662-8.
41. Chaichan W. Evaluation of the use of the positive and negative syndrome scale-excited component as a criterion for administration of p.r.n. medication. *J Psychiatr Pract*. 2008;14(2):105-13.
42. Holloman GH, Jr., Zeller SL. Overview of Project BETA: Best practices in Evaluation and Treatment of Agitation. *West J Emerg Med*. 2012;13(1):1-2.
43. Richardson SK, Grainger PC, Ardagh MW, Morrison R. Violence and aggression in the emergency department is under-reported and under-appreciated. *N Z Med J*. 2018;131(1476):50-8.
44. Huckshorn KA. Re-designing state mental health policy to prevent the use of seclusion and restraint. *Adm Policy Ment Health*. 2006;33(4):482-91.
45. Knox DK, Holloman GH, Jr. Use and avoidance of seclusion and restraint: consensus statement of the american association for emergency psychiatry project Beta seclusion and restraint workgroup. *West J Emerg Med*. 2012;13(1):35-40.
46. Battaglia J. Pharmacological management of acute agitation. *Drugs*. 2005;65(9):1207-22.
47. MacDonald K, Wilson MP, Minassian A, Vilke GM, Perez R, Cobb P, et al. A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug- and alcohol-using patients. *Gen Hosp Psychiatry*. 2010;32(4):443-5.
48. Vilke GM, Wilson MP, Lovecchio F. Agitation: what every emergency physician should know. *Emerg Med Rep*. 2009;30(19):233-43.
49. Pourshaikhian M, Abolghasem Gorji H, Aryankhesal A, Khorasani-Zavareh D, Barati A. A Systematic Literature Review: Workplace Violence Against Emergency Medical Services Personnel. *Arch Trauma Res*. 2016;5(1):e28734.
50. Petit JR. Management of the acutely violent patient. *Psychiatr Clin North Am*. 2005;28(3):701-11, 710.
51. Marco CA, Vaughan J. Emergency management of agitation in schizophrenia. *Am J Emerg Med*. 2005;23(6):767-76.
52. Peluso MJ, Lewis SW, Barnes TR, Jones PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. *Br J Psychiatry*. 2012;200(5):387-92.
53. Jibson MD. First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects. UptoDate Waltham, MA(Accessed June 17, 2014). 2014.
54. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. *J Clin Psychopharmacol*. 2008;28(2):203-9.
55. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet*. 2013;382(9896):951-62.
56. Baldacara L, Sanches M, Cordeiro DC, Jackowski AP. Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. *Braz J Psychiatry*. 2011;33(1):30-9.
57. Mantovani C, Migon MN, Alheira FV, Del-Ben CM. Management of the violent or agitated patient. *Braz J Psychiatry*. 2010;32 Suppl 2:S96-103.

58. Wilson MP, MacDonald K, Vilke GM, Feifel D. A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. *J Emerg Med.* 2012;43(5):790-7.
59. Huf G, Coutinho ES, Adams CE. Haloperidol plus promethazine for agitated patients--a systematic review. *Braz J Psychiatry.* 2009;31(3):265-70.
60. Food U, Administration D. Information for healthcare professionals: haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). US Food and Drug Administration Rockville, MD. 2007.
61. Meyer-Masseti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? *J Hosp Med.* 2010;5(4):E8-16.
62. Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. *Am J Health Syst Pharm.* 2008;65(11):1029-38.
63. Li M, Liz GR. Drug-Induced QT Prolongation And Torsades de Pointes. *P T.* 2017;42(7): 473-7.
64. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. *Curr Drug Saf.* 2010;5(1):97-104.
65. Muzyk AJ, Rayfield A, Revollo JY, Heinz H, Gagliardi JP. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol. *Drug Saf.* 2012;35(7):547-53.
66. Lopez-Munoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. *Ann Clin Psychiatry.* 2005;17(3):113-35.
67. Turner T. Chlorpromazine: unlocking psychosis. *BMJ.* 2007;334 Suppl 1:s7.
68. Excellence NifC. The short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments. London: NICE. 2005.
69. Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation. *Cochrane Database Syst Rev.* 2010(4):Cd007445.
70. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. *CNS drugs.* 2006;20(4):293-301.
71. Ucok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. *World psychiatry.* 2008;7(1):58-62.
72. Kroken RA, Johnsen E, Ruud T, Wentzel-Larsen T, Jorgensen HA. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. *BMC psychiatry.* 2009;9:24.
73. Marder SR. A review of agitation in mental illness: treatment guidelines and current therapies. *The J Clin Psychiatry.* 2006;67 Suppl 10:13-21.
74. Zeller SL, Rhoades RW. Systematic reviews of assessment measures and pharmacologic treatments for agitation. *Clin Ther.* 2010;32(3):403-25.
75. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. *N Engl J Med.* 2009;360(3):225-35.
76. Oliveira IR, Nunes PM, Coutinho DM, Sena EP. Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics. *Braz J Psychiatry.* 2009;31(1):52-6.
77. Brook S, Walden J, Benattia I, Siu CO, Romano SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. *Psychopharmacology.* 2005;178(4):514-23.
78. Satterthwaite TD, Wolf DH, Rosenheck RA, Gur RE, Caroff SN. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. *J Clin Psychiatry.* 2008;69(12):1869-79.
79. Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-

blind, placebo-controlled comparison with intramuscular haloperidol. *Psychopharmacology*. 2006;188(3):281-92.

80. Raveendran NS, Tharyan P, Alexander J, Adams CE. Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. *BMJ*. 2007;335(7625):865.

81. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. *J Clin Psychiatry*. 2007;68 Suppl 1:20-7.

82. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines: international survey and comparison. *Br J Psychiatry*. 2005;187:248-55.

83. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ, Jr., Okasha A, Singh B, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. *Schizophr Res*. 2008;100(1-3):20-38.

84. Centorrino F, Meyers AL, Ahl J, Cincotta SL, Zun L, Gulliver AH, et al. An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder. *Hum Psychopharmacol*. 2007;22(7):455-62.

85. Damsa C, Adam E, Lazignac C, De Gregorio F, Mihai A, Lejeune J, et al. Intramuscular olanzapine in patients with schizophrenia: an observational study in an emergency room. *Bull Soc Sci Med Grand Duche Luxemb*. 2008(2):209-16.

86. Jangro WC, Preval H, Southard R, Klotz SG, Francis A. Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study. *Child Adolesc Psychiatry Ment Health*. 2009;3(1):9.

87. Kohen I, Preval H, Southard R, Francis A. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service. *Am J Geriatr Pharmacother*. 2005;3(4):240-5.

88. Martel M, Sterzinger A, Miner J, Clinton J, Biroš M. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. *Acad Emerg Med*. 2005;12(12):1167-72.

89. Preval H, Klotz SG, Southard R, Francis A. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. *Gen Hosp Psychiatry*. 2005;27(2):140-4.

90. San L, Arranz B, Querejeta I, Barrio S, De la Gandara J, Perez V. A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. *Eur Psychiatry*. 2006;21(8):539-43.

91. Vesper FH, Vesper BD, McMullan JT, Zealberg J, Currier GW. Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. *J Psychiatr Pract*. 2006;12(2):103-8.

92. Zimbroff DL, Marcus RN, Manos G, Stock E, McQuade RD, Auby P, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. *J Clin Psychopharmacol*. 2007;27(2):171-6.

93. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2007;68(1):111-9.

94. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. *Arch Gen Psychiatry*. 2007;64(4):442-55.

95. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. *Bipolar Disord*. 2007;9(6):551-60.

96. Hsu WY, Huang SS, Lee BS, Chiu NY. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. *J Clin Psychopharmacol.* 2010;30(3):230-4.
97. Hatta K, Kawabata T, Yoshida K, Hamakawa H, Wakejima T, Furuta K, et al. Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients. *Gen Hosp Psychiatry.* 2008;30(4):367-71.
98. Lim HK, Kim JJ, Pae CU, Lee CU, Lee C, Paik IH. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. *Neuropsychobiology.* 2010;62(2):81-6.
99. Villari V, Rocca P, Fonzo V, Montemagni C, Pandullo P, Bogetto F. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. *Prog Neuropsychopharmacol Biol Psychiatry.* 2008;32(2):405-13.
100. Hovens JE, Dries PJ, Melman CT, Wapenaar RJ, Loonen AJ. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. *J Psychopharmacol.* 2005;19(1):51-7.
101. Pascual JC, Perez V, Martin JL, Safont G, Puigdemont D, Alvarez E. Olanzapine orally-disintegrating tablet in severe psychotic agitation: a naturalistic study. *Actas Esp Psiquiatr.* 2007;35(1):47-51.
102. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. *J Clin Psychiatry.* 2007;68(12):1876-85.
103. Mohr P, Pecenek J, Svestka J, Swingler D, Treuer T. Treatment of acute agitation in psychotic disorders. *Neuro Endocrinol Lett.* 2005;26(4):327-35.
104. Castle DJ, Udristoiu T, Kim CY, Sarosi A, Pidman V, Omar AN, et al. Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. *World J Biol Psychiatry.* 2009;10(1):43-53.
105. Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. *Schizophr Res.* 2006;86(1-3):234-43.
106. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet.* 2009;373(9657):31-41.
107. Belgamwar RB, Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. *Cochrane Database Syst Rev.* 2005(2):Cd003729.
108. Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. *J Clin Psychopharmacol.* 2008;28(6):601-7.
109. Marder SR, Sorsaburu S, Dunayevich E, Karagianis JL, Dawe IC, Falk DM, et al. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. *J Clin Psychiatry.* 2010;71(4):433-41.
110. Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. *Cochrane Database Syst Rev.* 2007(2):Cd005594.
111. Lilly E. Zyprexa (olanzapine) package insert. Indianapolis, IN. 2005.
112. Zacher JL, Roche-Desilets J. Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam. *J Clin Psychiatry.* 2005;66(12):1614-5.
113. Smith MA, McCoy R, Hamer-Maansson J, Brecher M. Rapid dose escalation with quetiapine: a pilot study. *J Clin Psychopharmacol.* 2005;25(4):331-5.
114. Currier GW, Trenton AJ, Walsh PG, van Wijngaarden E. A pilot, open-label safety study of quetiapine for treatment of moderate psychotic agitation in the emergency setting. *J Psychiatr Pract.* 2006;12(4):223-8.
115. Warrington L, Lombardo I, Loebel A, Ice K. Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder. *CNS drugs.* 2007;21(10):835-49.

116. Zimbroff DL, Allen MH, Battaglia J, Citrome L, Fishkind A, Francis A, et al. Best clinical practice with ziprasidone IM: update after 2 years of experience. *CNS Spectr*. 2005;10(9):1-15.
117. Barzman DH, DelBello MP, Forrester JJ, Keck PE, Jr., Strakowski SM. A retrospective chart review of intramuscular ziprasidone for agitation in children and adolescents on psychiatric units: prospective studies are needed. *J Child Adolesc Psychopharmacol*. 2007;17(4):503-9.
118. De Filippis S, Cuomo I, Lionetto L, Janiri D, Simmaco M, Caloro M, et al. Intramuscular aripiprazole in the acute management of psychomotor agitation. *Pharmacotherapy*. 2013;33(6):603-14.
119. Mauri MC, Steinhilber CP, Marino R, Invernizzi E, Fiorentini A, Cerveri G, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. *Eur Psychiatry*. 2005;20(1):55-60.
120. Nozawa M, Ohnuma T, Matsubara Y, Sakai Y, Hatano T, Hanzawa R, et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). *Ther Drug Monit*. 2008;30(1):35-40.
121. McIntyre J, Robertson S, Norris E, Appleton R, Whitehouse WP, Phillips B, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. *Lancet*. 2005;366(9481):205-10.
122. Mehta V, Singhi P, Singhi S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. *J Child Neurol*. 2007;22(10):1191-7.
123. Pellock JM, Shinnar S. Respiratory adverse events associated with diazepam rectal gel. *Neurology*. 2005;64(10):1768-70.
124. McMullan J, Sasson C, Pancioli A, Silbergleit R. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. *Acad Emerg Med*. 2010;17(6):575-82.
125. Vincent J-L, Shehabi Y, Walsh TS, Pandharipande PP, Ball JA, Spronk P, et al. Comfort and patient-centred care without excessive sedation: the eCASH concept. *Intensive Care Med*. 2016;42(6):962-71.
126. Rund DA, Ewing JD, Mitzel K, Votolato N. The use of intramuscular benzodiazepines and antipsychotic agents in the treatment of acute agitation or violence in the emergency department. *J Emerg Med*. 2006;31(3):317-24.
127. Licata SC, Platt DM, Cook JM, Van Linn ML, Rowlett JK. Contribution of alpha1 subunit-containing gamma-aminobutyric acidA (GABAA) receptors to motor-impairing effects of benzodiazepines in squirrel monkeys. *Psychopharmacology*. 2009;203(3):539-46.
128. Papineni A, Lourenco-Matharu L, Ashley PF. Safety of oral midazolam sedation use in paediatric dentistry: a review. *Int J Paediatr Dent*. 2014;24(1):2-13.
129. MacDonald K, Wilson M, Minassian A, Vilke GM, Becker O, Tallian K, et al. A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation. *J Clin Psychopharmacol*. 2012;32(3):317-22.
130. Gillies D, Beck A, McCloud A, Rathbone J, Gillies D. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. *Cochrane Database Syst Rev*. 2005(4):Cd003079.
131. Pacciardi B, Mauri M, Cargioli C, Belli S, Cotugno B, Di Paolo L, et al. Issues in the management of acute agitation: how much current guidelines consider safety? *Front Psychiatry*. 2013;4:26.
132. Arcangeli A, Antonelli M, Mignani V, Sandroni C. Sedation in PACU: the role of benzodiazepines. *Curr Drug Targets*. 2005;6(7):745-8.
133. Boomsma MM, Mengels O, van Olden RW. Risks associated with parenteral treatment of acute agitation. *Tijdschr Psychiatr*. 2006;48(2):135-9.
134. Wilson MP, MacDonald K, Vilke GM, Feifel D. Potential complications of combining intramuscular olanzapine with benzodiazepines in emergency department patients. *J Emerg Med*. 2012;43(5):889-96.
135. Cunha M, André S, Bica I, Ribeiro O, Dias A, Andrade A. Chemical and physical restraint of patients. *Procedia Soc Behav Sci*. 2016;217:389-99.

136. Leahy-Warren P, Varghese V, Day MR, Curtin M. Physical restraint: perceptions of nurse managers, registered nurses and healthcare assistants. *Int Nurs Rev.* 2018;65(3):327-35.
137. Gildberg FA, Fristed P, Makransky G, Moeller EH, Nielsen LD, Bradley SK. As time goes by: reasons and characteristics of prolonged episodes of mechanical restraint in forensic psychiatry. *J Forensic Nurs.* 2015;11(1):41-50.
138. Hui A, Middleton H, Völlm B. Coercive measures in forensic settings: Findings from the literature. *Int J Forensic Ment Health.* 2013;12(1):53-67.
139. Cannon M, Sprivulis P, McCarthy J. Restraint practices in Australasian emergency departments. *The Aust N Z J Psychiatry.* 2001;35(4):464-7.
140. Martin B, Mathisen L. Use of physical restraints in adult critical care: a bicultural study. *Am J Crit Care.* 2005;14(2):133-42.
141. Mason J, Colwell CB, Grock A. Agitation Crisis Control. *Ann Emerg Med.* 2018;72(4):371-3.
142. Coburn VA, Mycyk MB. Physical and chemical restraints. *Emerg Med Clin North Am.* 2009;27(4):655-67, ix.
143. Wilson EB. Physical restraint of elderly patients in critical care: historical perspectives and new directions. *Crit Care Nurs Clin North Am.* 1996;8(1):61-70.
144. Physicians ACoE. Use of patient restraints. Policy statement. *Ann Emerg Med.* 2014;64(5):574.
145. James A, Madeley R, Dove A. Violence and aggression in the emergency department. *Emerg Med J.* 2006;23(6):431-4.
146. Pich J, Hazelton M, Sundin D, Kable A. Patient-related violence at triage: A qualitative descriptive study. *Int Emerg Nurs.* 2011;19(1):12-9.
147. Baskin-Sommers A, Sommers I. Methamphetamine Use and Violence Among Young Adults. *J Crim Justice* 2006;34(6):661-74.
148. Holleran RS. Preventing staff injuries from violence. *J Emerg Nurs.* 2006;32(6):523-4.
149. Gates D, Ross C, McQueen L. Violence: Recognition, management and prevention. *J Emerg Med.* 2005;31(3):331-7.
150. Landau SF, Bendalak Y. Personnel exposure to violence in hospital emergency wards: a routine activity approach. *Aggress Behav.* 2008;34(1):88-103.
151. Gilchrist H, Jones SC, Barrie L. Experiences of emergency department staff: Alcohol-related and other violence and aggression. *Australas Emerg Nurs J.* 2011;14(1):9-16.
152. Gillespie GL, Gates DM, Miller M, Howard PK. Emergency department workers' perceptions of security officers' effectiveness during violent events. *Work.* 2012;42(1):21-7.
153. Wand TC, Coulson K. Zero tolerance: a policy in conflict with current opinion on aggression and violence management in health care. *Australas Emerg Nurs J.* 2006;9(4):163-70.
154. Mackay I, Paterson B, Cassells C. Constant or special observations of inpatients presenting a risk of aggression or violence: nurses' perceptions of the rules of engagement. *J Psychiatr Ment Health Nurs.* 2005;12(4):464-71.
155. Ramacciati N, Ceccagnoli A, Addey B, Rasero L. Violence towards Emergency Nurses. The Italian National Survey 2016: A qualitative study. *Int J Nurs Stud.* 2018;81:21-9.
156. Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP. The expert consensus guideline series. Treatment of behavioral emergencies 2005. *J Psychiatr Pract.* 2005;11 Suppl 1:5-108; quiz 10-2.
157. Currier GW. The controversy over "chemical restraint" in acute care psychiatry. *J Psychiatr Pract.* 2003;9(1):59-70.
158. Hopper AB, Vilke GM, Castillo EM, Campillo A, Davie T, Wilson MP. Ketamine use for acute agitation in the emergency department. *J Emerg Med.* 2015;48(6):712-9.
159. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. *J Clin Psychiatry.* 2004;65 Suppl 2:5-99; discussion 100-2; quiz 3-4.

160. Gerson R, Malas N, Mroczkowski MM. Crisis in the Emergency Department: The Evaluation and Management of Acute Agitation in Children and Adolescents. *Child Adolesc Psychiatr Clin N Am*. 2018;27(3):367-86.
161. Vieta E, Garriga M, Cardete L, Bernardo M, Lombrana M, Blanch J, et al. Protocol for the management of psychiatric patients with psychomotor agitation. *BMC psychiatry*. 2017;17(1):328.
162. Larue C, Dumais A, Ahern E, Bernheim E, Mailhot MP. Factors influencing decisions on seclusion and restraint. *J Psychiatr Ment Health Nurs*. 2009;16(5):440-6.
163. Farina-Lopez E, Estevez-Guerra GJ, Polo-Luque ML, Hanzelikova Pogranyiva A, Penelo E. Physical Restraint Use With Elderly Patients: Perceptions of Nurses and Nursing Assistants in Spanish Acute Care Hospitals. *Nurs Res*. 2018;67(1):55-9.
164. Laiho T, Kattainen E, Astedt-Kurki P, Putkonen H, Lindberg N, Kylma J. Clinical decision making involved in secluding and restraining an adult psychiatric patient: an integrative literature review. *J Psychiatr Ment Health Nurs*. 2013;20(9):830-9.
165. Kallert TW. Involuntary psychiatric hospitalization: current status and future prospects. *Srp Arh Celok Lek*. 2011;139 Suppl 1:14-20.
166. Hodge AN, Marshall AP. Violence and aggression in the emergency department: a critical care perspective. *Aust Crit Care*. 2007;20(2):61-7.
167. Perkins E, Prosser H, Riley D, Whittington R. Physical restraint in a therapeutic setting; a necessary evil? *Int J Law Psychiatry*. 2012;35(1):43-9.
168. De Hert M, Einfinger G, Scherpenberg E, Wampers M, Peuskens J. The prevention of deep venous thrombosis in physically restrained patients with schizophrenia. *Int J Clin Pract*. 2010;64(8):1109-15.
169. Maly R, Masopust J, Hosak L, Konupcikova K. Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients. *Psychiatry Clin Neurosci*. 2008;62(1):3-8.
170. Steinert T, Lepping P, Bernhardsgrutter R, Conca A, Hatling T, Janssen W, et al. Incidence of seclusion and restraint in psychiatric hospitals: a literature review and survey of international trends. *Soc Psychiatry Psychiatr Epidemiol*. 2010;45(9):889-97.
171. Cecchi R, Lazzaro A, Catanese M, Mandarelli G, Ferracuti S. Fatal thromboembolism following physical restraint in a patient with schizophrenia. *Int J Legal Med*. 2012;126(3):477-82.
172. Dickson BC, Pollanen MS. Fatal thromboembolic disease: a risk in physically restrained psychiatric patients. *J Forensic Leg Med*. 2009;16(5):284-6.
173. Ishida T, Katagiri T, Uchida H, Takeuchi H, Sakurai H, Watanabe K, et al. Incidence of deep vein thrombosis in restrained psychiatric patients. *Psychosomatics*. 2014;55(1):69-75.
174. Karger B, Fracasso T, Pfeiffer H. Fatalities related to medical restraint devices-asphyxia is a common finding. *Forensic Sci Int*. 2008;178(2-3):178-84.
175. Laursen SB, Jensen TN, Bolwig T, Olsen NV. Deep venous thrombosis and pulmonary embolism following physical restraint. *Acta Psychiatr Scand*. 2005;111(4):324-7; discussion 7.
176. Rakhmatullina M, Taub A, Jacob T. Morbidity and mortality associated with the utilization of restraints : a review of literature. *Psychiatr Q*. 2013;84(4):499-512.
177. Cowman S, Bjorkdahl A, Clarke E, Gethin G, Maguire J. A descriptive survey study of violence management and priorities among psychiatric staff in mental health services, across seventeen european countries. *BMC Health Serv Res*. 2017;17(1):59.
178. Nelstrop L, Chandler-Oatts J, Bingley W, Bleetman T, Corr F, Cronin-Davis J, et al. A systematic review of the safety and effectiveness of restraint and seclusion as interventions for the short-term management of violence in adult psychiatric inpatient settings and emergency departments. *Worldviews Evid Based Nurs*. 2006;3(1):8-18.
179. Paterson B, McIntosh I, Wilkinson D, McComish S, Smith I. Corrupted cultures in mental health inpatient settings. Is restraint reduction the answer? *J Psychiatr Ment Health Nurs*. 2013;20(3):228-35.

180. An FR, Sha S, Zhang QE, Ungvari GS, Ng CH, Chiu HF, et al. Physical restraint for psychiatric patients and its associations with clinical characteristics and the National Mental Health Law in China. *Psychiatry Res.* 2016;241:154-8.
181. Steinert T, Lepping P. Legal provisions and practice in the management of violent patients. a case vignette study in 16 European countries. *Eur Psychiatry.* 2009;24(2):135-41.
182. Azeem MW, Aujla A, Rammerth M, Binsfeld G, Jones RB. Effectiveness of six core strategies based on trauma informed care in reducing seclusions and restraints at a child and adolescent psychiatric hospital. *J Child Adolesc Psychiatr Nurs.* 2011;24(1):11-5.
183. Hellerstein DJ, Staub AB, Lequesne E. Decreasing the use of restraint and seclusion among psychiatric inpatients. *J Psychiatr Pract.* 2007;13(5):308-17.
184. Martin A, Krieg H, Esposito F, Stubbe D, Cardona L. Reduction of restraint and seclusion through collaborative problem solving: a five-year prospective inpatient study. *Psychiatr Serv.* 2008;59(12):1406-12.
185. Currier GW, Walsh P, Lawrence D. Physical restraints in the emergency department and attendance at subsequent outpatient psychiatric treatment. *J Psychiatr Pract.* 2011;17(6):387-93.
186. Demir A. Nurses' use of physical restraints in four Turkish hospitals. *J Nurs Scholarsh.* 2007;39(1):38-45.
187. Downes MA, Healy P, Page CB, Bryant JL, Isbister GK. Structured team approach to the agitated patient in the emergency department. *Emerg Med Australas.* 2009;21(3):196-202.
188. Dumais A, Larue C, Drapeau A, Menard G, Giguere Allard M. Prevalence and correlates of seclusion with or without restraint in a Canadian psychiatric hospital: a 2-year retrospective audit. *J Psychiatr Ment Health Nurs.* 2011;18(5):394-402.
189. Lane C, Harrington A. The factors that influence nurses' use of physical restraint: A thematic literature review. *Int J Nurs Pract.* 2011;17(2):195-204.
190. Gelkopf M, Roffe Z, Behrbalk P, Melamed Y, Werbloff N, Bleich A. Attitudes, opinions, behaviors, and emotions of the nursing staff toward patient restraint. *Issues Ment Health Nurs.* 2009;30(12):758-63.
191. Gerace A, Pamungkas DR, Oster C, Thomson D, Muir-Cochrane E. The use of restraint in four general hospital emergency departments in Australia. *Australas Psychiatry.* 2014;22(4):366-9.
192. Raboch J, Kalisova L, Nawka A, Kitzlerova E, Onchev G, Karastergiou A, et al. Use of coercive measures during involuntary hospitalization: findings from ten European countries. *Psychiatr Serv.* 2010;61(10):1012-7.
193. Knutzen M, Sandvik L, Hauff E, Opjordsmoen S, Friis S. Association between patients' gender, age and immigrant background and use of restraint--a 2-year retrospective study at a department of emergency psychiatry. *Nord J Psychiatry.* 2007;61(3):201-6.
194. Knutzen M, Bjorkly S, Eidhammer G, Lorentzen S, Helen Mjosund N, Opjordsmoen S, et al. Mechanical and pharmacological restraints in acute psychiatric wards--why and how are they used? *Psychiatry Res.* 2013;209(1):91-7.
195. Knutzen M, Bjorkly S, Eidhammer G, Lorentzen S, Mjosund NH, Opjordsmoen S, et al. Characteristics of patients frequently subjected to pharmacological and mechanical restraint--a register study in three Norwegian acute psychiatric wards. *Psychiatry Res.* 2014;215(1):127-33.
196. Kontio R, Joffe G, Putkonen H, Kuosmanen L, Hane K, Holi M, et al. Seclusion and restraint in psychiatry: patients' experiences and practical suggestions on how to improve practices and use alternatives. *Perspect Psychiatr Care.* 2012;48(1):16-24.
197. Mayers P, Keet N, Winkler G, Flisher AJ. Mental health service users' perceptions and experiences of sedation, seclusion and restraint. *Int J Soc Psychiatry.* 2010;56(1):60-73.
198. McCurdy JM, Haliburton JR, Yadav HC, Yoder AM, Norton LR, Froehlich JA, et al. Case study: design may influence use of seclusion and restraint. *Herd.* 2015;8(3):116-21.

199. Migon MN, Coutinho ES, Huf G, Adams CE, Cunha GM, Allen MH. Factors associated with the use of physical restraints for agitated patients in psychiatric emergency rooms. *Gen Hosp Psychiatry*. 2008;30(3):263-8.
200. Khatib A, Ibrahim M, Roe D. Re-building Trust after Physical Restraint During Involuntary Psychiatric Hospitalization. *Arch Psychiatr Nurs*. 2018;32(3):457-61.

Archive of SID